Efforts to reform federal drug pricing program 340B continue with new report, proposed CMS rule

Efforts to overhaul the federal drug pricing program 340B are gaining momentum with a new report and proposed CMS rule. This initiative seeks to address issues where some providers misused the program to profit instead of serving underserved patients. These reforms are crucial as the 340B program was designed to help hospitals and clinics offer affordable care. If implemented, these changes could restore integrity to the program, ensuring it fulfills its original mission of providing discounts to genuinely needy patients.